Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can AI read a Tumor's DNA to predict which breast cancer drug will work?

NCT ID NCT07066917

Knowledge-focused Sponsor: Hellenic Cooperative Oncology Group Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Oct 14, 2026 · Last updated Oct 15, 2026 · Updated 1 time

Summary

Researchers are collecting blood, tumor and imaging data from 150 adults with locally advanced or metastatic breast cancer to understand why some treatments work and others stop working. The study follows people who receive standard modern therapies such as CDK inhibitors, antibody-drug conjugates, immune checkpoint inhibitors and PARP inhibitors. Using whole exome sequencing, circulating tumor DNA analysis, digital pathology and radiomics, the team aims to build a machine-learning tool that predicts response or resistance based on each patient's genetics and tumor profile.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If it works, this could give doctors a data-driven way to pick the best treatment sequence for each person with advanced breast cancer and avoid drugs that are unlikely to help.
What could go wrong
This is an observational study, so it does not test a new treatment and cannot prove that any biomarker-guided choice improves survival. The machine-learning tool may not generalize beyond the 150 participants or the specific treatments they receive.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 150 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2024

Expected to finish

Oct 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study will include patients with histologically confirmed, advanced breast cancer of one of the following subtypes: i) Hormone receptor positive and/or ii) HER2-positive or -low or iii) triple negative breast cancer (TNBC)

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Eligible patients will be 18 years of age and older * Histologically confirmed, advanced breast cancer. * Diagnosis of i) hormone receptor positive and/or ii) HER2-positive or -low or iii) triple negative breast cancer (TNBC). * Patients will be included in the analysis after receiving at least one treatment cycle. Exclusion Criteria: * Diagnosis of early breast cancer at time of enrollment * Unwillingness to provide informed consent * Unwillingness to provide biological specimen * Lack of comprehensive clinical data

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HER2-positive breast cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm HER2 positive breast carcinoma hormone receptor-positive breast cancer triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Metastatic breast cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    5 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • "MITERA" Hospital, Dept. of Medical Oncology

    RECRUITING

    Athens, GR 15123, Greece

  • Metropolitan Hospital, 2nd Dept. of Medical Oncology

    RECRUITING

    Athens, GR 18547, Greece

  • Metropolitan Hospital, 4th Dept. of Medical Oncology

    RECRUITING

    Athens, GR 18547, Greece

  • St. Luke's Hospital, Dept. of Medical Oncology

    RECRUITING

    Thessaloniki, GR 55236, Greece

  • University General Hospital "ATTIKON", 2nd propedeutic dept. of Internal Medicine

    RECRUITING

    Athens, GR 12462, Greece

More trials for these conditions

Other studies related to the condition(s) this trial covers.